Takeda Pharmaceutical is buying the venture-funded drug discovery company Envoy Therapeutics for up to $140 million, a purchase price that includes an up-front payment and milestone payments. This isn't the first time Takeda has put money into Envoy. Back in October 2009, Takeda’s corporate venture arm, Takeda Ventures, participated in Envoy’s Series A financing. Envoy is also funded by 5AM Ventures and Roche Venture Fund. Envoy's proprietary bacTRAP technology combines genetic engineering with new molecular biology techniques for labeling and extracting the protein-making components of specific types of cells.